Comparing Carboplatin with Echocardiography Test for low grade astrocytoma

Inclusion

• +Patients 2-17 years of age must have a blood pressure that is =\< 95th percentile for age, height, and sex at the time of enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more → (with or without the use of anti-hypertensive medications)
• +Patients with metastatic disease or multiple independent primary LGG are eligible
• +All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
• +Patients must be \>= 2 years and =\< 21 years at the time of enrollment
• +Patients must have a body surface area (BSA) of \>= 0.5 m\^2 at enrollment
• +Patients must have two-dimensional measurable tumor \>= 1 cm\^2 to be eligible
• +Patients with ependymoma are not eligible
• +Eligible histologies will include all tumors considered low-grade glioma or low-grade astrocytoma (World Health Organization \[WHO\] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma
• +Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/sex as follows (performed within 7 days prior to enrollment):
• +Age: Maximum Serum Creatinine (mg/dL)
• +2 to \< 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
• +6 to \< 10 years: 1 mg/dL (male); 1 mg/dL (female)
• +10 to \< 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female)
• +13 to \< 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
• +\>= 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
• +Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment) (children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect \[unconjugated\] bilirubin levels as long as their direct \[conjugated\] bilirubin is \< 3.1 mg/dL)
• +Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (performed within 7 days prior to enrollment). For the purpose of this study, the ULN for SGPT is 45 U/L
• +Albumin \>= 2 g/dL (performed within 7 days prior to enrollment)
• +Left ventricular ejection fraction (LVEF) \>= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram (performed within 4 weeks prior to enrollment)
• +Corrected QT (QTc) interval =\< 450 msec by electrocardiography (EKG) (performed within 4 weeks prior to enrollment)
• +Absolute neutrophil count \>= 1,000/uL (unsupported) (performed within 7 days prior to enrollment)
• +Platelets \>= 100,000/uL (unsupported) (performed within 7 days prior to enrollment)
• +Hemoglobin \>= 8 g/dL (may be supported) (performed within 7 days prior to enrollment)
• +Patients with a known seizure disorder must be stable and must not have experienced a significant increase in seizure frequency within 2 weeks prior to enrollment
• +Patients \>= 18 years of age must have a blood pressure =\< 130/80 mmHg at the time of enrollment (with or without the use of anti-hypertensive medications)
• +Note for patients of all ages: Adequate blood pressure can be achieved using medication for the treatment of hypertension
• +All patients must have ophthalmology toxicity assessments performed within 8 weeks prior to enrollment
• +For all patients, an MRI of the brain (with orbital cuts for optic pathway tumors) and/or spine (depending on the siteTrial siteA hospital or clinic where a study is actually run.Read more →(s) of primary disease) with and without contrast must be performed within 8 weeks prior to enrollment
• +Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age
• +Patients must have the ability to swallow whole capsules
• +All patients and/or their parents or legal guardians must sign a written informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
• +All patients have signed an appropriate consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form (if applicable)
• +All patients have been consented and enrolled on APEC14B1 (NCT02402244) Part A for Pre-Enrollment EligibilityEligibility criteriaThe full list of requirements for taking part in a study.Read more → ScreeningScreeningThe checks done before joining, to see whether a study fits.Read more → for ACNS1833
• +Patients must have non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1 (NCT02402244) Childhood Cancer Data Initiative (CCDI)-MCI, or accepted Clinical Laboratory Improvement Act (CLIA)-certified test and that has not been treated with any modality besides surgery. Note: Patients may be newly-diagnosed OR previously diagnosed, and there is no required time frame between biopsy/surgery and treatment initiation.
• +Patients with residual tumor after resection or progressive tumor after initial diagnosis (with or without surgery) who have not received treatment (chemotherapy and/or radiation) are eligible